366 results on '"Cahn, Pedro"'
Search Results
2. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
3. Dual therapy based on co-formulated darunavir/ritonavir plus lamivudine for initial therapy of HIV infection: The ANDES randomized controlled trial
4. Oral and anal microbiome from HIV-exposed individuals: role of host-associated factors in taxa composition and metabolic pathways
5. Identifying the needs of older people living with HIV (≥ 50 years old) from multiple centres over the world: a descriptive analysis
6. Mpox in people with advanced HIV infection: a global case series
7. Two-drug regimens for HIV treatment
8. A small cluster randomised clinical trial to improve health outcomes among Argentine patients disengaged from HIV care
9. Late-onset opportunistic infections while receiving anti-retroviral therapy in Latin America: burden and risk factors
10. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
11. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
12. Latin America Priorities after 40 years of the beginning of the HIV pandemic
13. RBD-specific polyclonal F(ab´)2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
14. Cumulative Burden of Mental Health Factors and Engagement in HIV Care in Argentina
15. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
16. Service delivery challenges in HIV care during the first year of the COVID‐19 pandemic: results from a site assessment survey across the global IeDEA consortium
17. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study
18. Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
19. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
20. The HIV epidemic in Latin America: a time to reflect on the history of success and the challenges ahead
21. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1
22. Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial
23. Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection
24. Liver cirrhosis in HIV/HCV-coinfected individuals is related to NK cell dysfunction and exhaustion, but not to an impaired NK cell modulation by CD4+ T-cells
25. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
26. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
27. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials
28. Expert consensus statement on the science of HIV in the context of criminal law
29. Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean Cohort
30. Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort study
31. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial
32. Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosa
33. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
34. The HIV care cascade in Buenos Aires, Argentina: results in a tertiary referral hospital/ La cascada en la atencion de la infeccion por el VIH en Buenos Aires, Argentina resultados en un hospital de referencia de atencion terciaria
35. Lopinavir/ritonavir en nuevas estrategias de tratamiento antirretroviral de inicio
36. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial
37. Fostemsavir: a new CD4 attachment inhibitor
38. Physician-delivered motivational interviewing to improve adherence and retention in care among challenging HIV-infected patients in Argentina (COPA2): study protocol for a cluster randomized controlled trial
39. Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America
40. Improving Adherence to Care Among “Hard to Reach” HIV-Infected Patients in Argentina
41. Boosting HIV Treatment Options: Good News, New Challenges
42. Monitoring of HIV treatment in seven countries in the WHO Region of the Americas/Suivi du traitement du VIH dans sept pays de la Region OMS des Ameriques/Monitoreo del tratamiento del VIH en siete paises de la Region de las Americas de la OMS
43. Universal Access in the Fight Against HIV/AIDS
44. Hepatitis B Virus, Hepatitis C Virus and HIV Coinfection Among People Living With HIV/AIDS in Buenos Aires, Argentina
45. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
46. Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
47. "If I'm at home, I do it at home": Qualitative study on HIV self-testing among transgender women in Argentina.
48. Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1-Infected Patients: The MaxCminl Trial
49. A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4⁺ Cell Counts ⩾350/mm³
50. Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment‐limited individuals living with HIV.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.